Aurobindo Pharma Outperforms Expectations with Strong Q4, Eyes Robust Growth Ahead By Investing.com
Aurobindo Pharma (NS:) outperformed expectations in 4QFY24, with both sales and EBITDA showing significant year-on-year growth. Sales rose 17%, while EBITDA rose an impressive 68%, beating Goldman Sachs (NYSE:) expectations and…
